USD
+$0.00
(+0.00%
)At Close (As of Sep 3, 2025)
$48.38M
Market Cap
-
P/E Ratio
-1.21
EPS
$3.95
52 Week High
$0.69
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | $1.9M |
Total Revenue | $5.7M |
Cost Of Revenue | $3.8M |
Costof Goods And Services Sold | $3.8M |
Operating Income | -$81M |
Selling General And Administrative | $19M |
Research And Development | $67M |
Operating Expenses | $86M |
Investment Income Net | - |
Net Interest Income | $5.2M |
Interest Income | $5.2M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.8M |
Income Before Tax | -$75M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$75M |
Comprehensive Income Net Of Tax | - |
Ebit | -$81M |
Ebitda | -$77M |
Net Income | -$75M |
Field | Value (USD) |
---|---|
Total Assets | $91M |
Total Current Assets | $79M |
Cash And Cash Equivalents At Carrying Value | $57M |
Cash And Short Term Investments | $57M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $12M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $16M |
Other Current Assets | $6.2M |
Other Non Current Assets | - |
Total Liabilities | $11M |
Total Current Liabilities | $8.9M |
Current Accounts Payable | $2.4M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $900K |
Total Non Current Liabilities | $2.5M |
Capital Lease Obligations | $3.4M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $3.4M |
Other Current Liabilities | $5.6M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $80M |
Treasury Stock | - |
Retained Earnings | -$382M |
Common Stock | $5K |
Common Stock Shares Outstanding | $51M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$61M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $3.8M |
Capital Expenditures | $59K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$8.5M |
Cashflow From Financing | $787K |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$17K |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$75M |
Field | Value (USD) |
---|---|
Gross Profit | $1.9M |
Total Revenue | $5.7M |
Cost Of Revenue | $3.8M |
Costof Goods And Services Sold | $3.8M |
Operating Income | -$81M |
Selling General And Administrative | $19M |
Research And Development | $67M |
Operating Expenses | $86M |
Investment Income Net | - |
Net Interest Income | $5.2M |
Interest Income | $5.2M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.8M |
Income Before Tax | -$75M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$75M |
Comprehensive Income Net Of Tax | - |
Ebit | -$81M |
Ebitda | -$77M |
Net Income | -$75M |
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is headquartered in Austin, Texas.